NTRK1/2/3 CDx
- NTRK1/2/3 CDx is the first NGS-based companion diagnostic product in pan-solid tumor , which comprehensively covers 18–20 million patients with solid tumors in China.
- It will be used as a companion diagnostic to identify patients with NTRK1/2/3 fusions solid tumors who may be appropriate for treatment with Bayer's larotrectinib.
- NTRK1/2/3 CDx developed by OrigiMed in cooperation with Bayer granted the Special Review Procedure for Innovative Medical Devices by the National Medical Products Administration (NMPA) of China.
- NTRK1/2/3 CDx has completed EU CE certification and obtained the registration license issued by CIBG.